Antibody-conjugated drugs combine with specific antigens on the surface of cancer cells to deliver the toxic compounds carried into the cells, thereby killing cancer cells while avoiding damage to healthy cells. Zynlonta is an ADC composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin.
